Armata Pharmaceuticals, Inc. (ARMP) - 10-Q Summary
Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc.
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company operates as a single segment focused on two lead candidates: AP-PA02 (for Pseudomonas aeruginosa) and AP-SA02 (for Staphylococcus aureus).
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Grant and Award Revenue | $2,169 | $0 | $2,660 | $966 |
| Total Operating Expenses | $9,013 | $11,914 | $17,695 | $23,108 |
| Net Loss | $(16,295) | $8,986 (Income) | $(22,826) | $(16,035) |
| Cash and Cash Equivalents | $4,328 | $9,291 (Dec 2024) | $4,328 | $26,405 (Dec 2023) |
| Restricted Cash | $5,390 | $5,480 (Dec 2024) | $5,390 | $5,480 (Dec 2023) |
| Total Debt (Current + Non-Current) | $112,336 | $61,493 (Dec 2024) | $112,336 | $61,493 (Dec 2023) |
| Accumulated Deficit | $(350,561) | $(327,735) (Dec 2024) | $(350,561) | $(327,735) (Dec 2023) |
Note: Debt figures include Convertible Loan ($33.4M) and Term Debt ($78.9M). Q2 2024 net income was driven by a $23.4M gain on the change in fair value of the Convertible Loan.
Material Changes vs. Prior Period
- Revenue: Grant and award revenue increased significantly to $2.2M in Q2 2025 (from $0 in Q2 2024) due to cost reimbursements from the MTEC award for the AP-SA02 program.
- Operating Expenses: Total operating expenses decreased by 24.3% in Q2 2025 compared to Q2 2024. R&D expenses dropped $2.1M, primarily due to reduced clinical trial costs for the AP-PA02 Non-Cystic Fibrosis Bronchiectasis (NCFB) study.
- Net Loss: The company reported a net loss of $16.3M in Q2 2025, compared to a net income of $9.0M in Q2 2024. The prior year income was largely non-cash, driven by a $23.4M gain on the fair value adjustment of the Convertible Loan. In Q2 2025, the company recorded a $5.8M loss on the same metric.
- Liquidity: Cash and cash equivalents declined from $9.3M at year-end 2024 to $4.3M at June 30, 2025. Net cash used in operating activities was $14.8M for the six months ended June 30, 2025.
Guidance, Outlook, and Risks
- Going Concern: Management states that existing cash ($4.3M) is insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern. Additional capital is required.
- Recent Financing:
- March 2025: Secured a $10.0M term loan from Innoviva at 14% interest, maturing March 2026.
- August 2025 (Subsequent Event): Entered into a $15.0M credit agreement with Innoviva at 14% interest, maturing January 2029.
- Clinical Progress:
- AP-SA02: Announced positive topline data from the Phase 1b/2a diSArm study for S. aureus bacteremia in May 2025. The study showed a statistically significant increase in responder rates (88% vs 58% placebo) at Test of Cure.
- AP-PA02: Completed Phase 2 "Tailwind" study in NCFB patients in December 2024 with encouraging results. Future Phase 3 development is contingent on securing funding.
- Risks: High interest rates on debt (14%), reliance on non-dilutive grants (MTEC), and the need for immediate equity or debt financing to avoid operational curtailment.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the new $15M August 2025 loan combined with existing cash to cover the burn rate through the next 12-18 months.
- Debt Covenants: Review the specific financial covenants and maturity dates of the Innoviva loans (March 2026 and January 2029) and the Convertible Loan.
- Grant Sustainability: Confirm the remaining unspent balance of the $26.2M MTEC award and the timeline for recognizing the remaining revenue.
- Dilution Risk: Assess the potential dilution from the Convertible Loan ($30M principal + accrued interest) which can be converted into ~23.7M shares at $1.52/share.
- Clinical Next Steps: Monitor the timeline for the planned End-of-Phase 2 meeting with the FDA for AP-SA02 and the decision on initiating a Phase 3 trial for AP-PA02.